GE HealthCare: Solid Growth, But Price Outpaces Fair Value of $158
By stockpickr AI | March 2, 2026 | 10 min read
Investment Summary
GE HealthCare is a leading medical technology provider showing solid revenue growth and strong margins, suggesting it may be slightly overvalued based on current DCF projections compared to its recent trading price.
Investment Recommendation
Hold
Fair Value: $158.50
Current Price: $166.95
Upside/Downside: -4.94%
The DCF analysis suggests an implied fair value slightly below the current market price, indicating that the stock is currently trading at a premium reflecting high investor expectations for future growth. While the business fundamentals are strong, the valuation requires patience.
Key Metrics
- Market Cap: $80.73B
- P/E Ratio: 36.55x
- Forward P/E: 18.29x
- Revenue Growth (YoY): 7.8%
- Net Margin: 11.4%
- ROE: 21.5%
- Debt/Equity: 1.61
- Dividend Yield: 0.77%
Strengths
- Strong backlog: Order backlog remained strong at $11.4 billion as of Q1 2024, indicating robust future revenue visibility.
- High profitability: Trailing twelve months (TTM) net income margin stands at approximately 11.4%, demonstrating operational efficiency.
- Market leadership: Dominant position in key segments like MRI and Ultrasound, benefiting from essential healthcare spending.
- Healthy Return on Equity: ROE of 21.5% indicates efficient use of shareholder capital.
Risk Factors
- High Leverage: Debt-to-Equity ratio of 1.61 suggests significant leverage following the spin-off and associated financing activities.
- Valuation Premium: Current P/E ratio (36.55) is notably higher than historical averages and some peers, suggesting valuation sensitivity.
- Currency Headwinds: Significant international revenue base exposes earnings to adverse foreign exchange fluctuations.